Mumbai based Centaur Pharmaceuticals has recently announced the launch of a New Chemical Entity (NCE)- WOXheal®, for the first time in the world. With its dual mechanism of action, WOXheal® is a unique product in the treatment of diabetic foot ulcers, and it will save millions of diabetics who have to undergo foot amputation globally.
Diabetic foot ulcer is the most common complication seen in India. Data indicates that 25% of people with Diabetes, will develop a Diabetic Foot Ulcer in their lifetime. 1 in 5 Diabetics who are hospitalized due to severe foot infection, undergo a foot amputation affecting the livelihood of the family.
A globally patented product, WOXheal® topical solution, is effective in treating Diabetic foot ulcers. WOXheal® contains the NCE, Diperoxochloric acid, also called as DPOCL. WOXheal® has dual mechanism of action, i.e. it has functional antibacterial action against Gram-positive and Gram-negative bacteria and it also promotes the growth of fibroblast cells, thereby yielding complete wound closure.
Randomized clinical trials conducted across India in over 15 clinical trial centres on WOXheal® elucidated that over 90 per cent of patients with non-healing diabetic foot ulcer showed a reduction in the size of the ulcer, and 75% out of these patients achieved complete healing within 6-8 weeks without any safety issue. The data and outcomes of the trial were submitted to the Indian Regulatory Authority and a manufacturing and marketing approval was granted to Centaur Pharmaceuticals for WOXheal®.
